Bergenbio ASA Current Valuation vs. EBITDA
| BGBIO Stock | NOK 10.87 0.48 4.23% |
For Bergenbio ASA profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bergenbio ASA to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bergenbio ASA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bergenbio ASA's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bergenbio ASA over time as well as its relative position and ranking within its peers.
Bergenbio |
Bergenbio ASA EBITDA vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Bergenbio ASA's current stock value. Our valuation model uses many indicators to compare Bergenbio ASA value to that of its competitors to determine the firm's financial worth. Bergenbio ASA is the top company in current valuation category among its peers. It also is number one stock in ebitda category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bergenbio ASA by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bergenbio ASA's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Bergenbio Current Valuation vs. Competition
Bergenbio ASA is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 9.06 Billion. Bergenbio ASA holds roughly 421.26 Million in current valuation claiming about 5% of equities under Health Care industry.
Bergenbio EBITDA vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Bergenbio ASA |
| = | 421.26 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Bergenbio ASA |
| = | (308 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Bergenbio EBITDA Comparison
Bergenbio ASA is currently under evaluation in ebitda category among its peers.
Bergenbio ASA Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Bergenbio ASA, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bergenbio ASA will eventually generate negative long term returns. The profitability progress is the general direction of Bergenbio ASA's change in net profit over the period of time. It can combine multiple indicators of Bergenbio ASA, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. The company was founded in 2007 and is headquartered in Bergen, Norway. BerGenBio ASA is traded on Oslo Stock Exchange in Norway.
Bergenbio Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Bergenbio ASA. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bergenbio ASA position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bergenbio ASA's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Bergenbio ASA without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
Use Investing Themes to Complement your Bergenbio ASA position
In addition to having Bergenbio ASA in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cars Thematic Idea Now
Cars
Domestic and international companies involved in manufacturing and serving automobiles and trucks. The Cars theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cars Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Bergenbio Stock
To fully project Bergenbio ASA's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bergenbio ASA at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bergenbio ASA's income statement, its balance sheet, and the statement of cash flows.